The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 4, 2015, Pages 358-364

  Lowes, L E ^a,b   Lock, M ^a,b   Rodrigues, G ^a,b   D'Souza, D ^a,b   Bauman, G ^a,b   Ahmad, B ^a,b   Venkatesan, V ^a,b   Allan, A L ^a,b   Sexton, T ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BIOCHEMICAL RECURRENCE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CIRCULATING TUMOR CELL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SEMINAL VESICLE; TUMOR INVASION; ADJUVANT RADIOTHERAPY; BLOOD; CANCER GRADING; CANCER STAGING; CELL COUNT; FOLLOW UP; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CELL COUNT; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84947022189     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.36     Document Type: Article

References (16)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.
3. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?. J Urol. 1994; 152: 1843-1849.
4. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24: 395-406.
5. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439.
6. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14: 6302-6309.
7. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011; 57: 1242-1255.
8. Olmos D, Arkenau H-T, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009; 20: 27-33.
9. Danila DC, Heller G, Gignac G a, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13: 7053-7058.
10. Murray NP, Reyes E, Tapia P, Badinez L, Orellana N, Fuentealba C, et al. Redefining micrometastasis in prostate cancer - A comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: implications in determining local or systemic treatment for biochemical failure after radical prostatecto. Int J Mol Med. 2012; 30: 896-904.
11. Murray NP, Reyes E, Orellana N, Fuentealba C, Bádinez L, Olivares R, et al. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease. ScientificWorldJournal. 2013; 2013: 762064.
12. Tombal B, Van Cangh PJ, Loric S, Gala J-L. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate. 2003; 56: 163-170.
13. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013; 190: 441-449.
14. Lowes LE, Lock M, Rodrigues G, D'Souza D, Bauman G, Ahmad B, et al. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clin Transl Oncol. 2012; 14: 150-156.
15. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003; 21: 483-489.
16. Alix-Panabières C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip. 2014; 14: 57-62.